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Abstract  63 
Introduction: Discriminating between placentally-mediated fetal growth restriction and constitutionally-64 
small fetuses is a challenge in obstetric practice. Placental growth factor (PlGF), measurable in the 65 
maternal circulation, may have this discriminatory capacity.   66 
Methods: Plasma PlGF was measured in women presenting with suspected fetal growth restriction 67 
(FGR; ultrasound fetal abdominal circumference <10
th
 percentile for gestational age) at sites in Canada, 68 
New Zealand and the United Kingdom. When available, placenta tissue underwent histopathological 69 
examination for lesions indicating placental dysfunction, blinded to PlGF and clinical outcome. Lesions 70 
were evaluated according to pre-specified severity criteria and an overall severity grade was assigned 71 
(0–3, absent to severe). Low PlGF (concentration <5
th
 percentile for gestational age) to identify placental 72 
FGR (severity grade ≥2) was assessed and compared with routine parameters for fetal assessment. For 73 
all cases, the relationship between PlGF and the sampling-to-delivery interval was determined. 74 
Results: Low PlGF identified placental FGR with an area under the receiver-operator characteristic curve 75 
of 0.96 [95% CI 0.93‒0.98], 98.2% [95% CI 90.5‒99.9] sensitivity and 75.1% [95% CI 67.6‒81.7] 76 
specificity. Negative and positive predictive values were 99.2% [95% CI 95.4‒99.9] and 58.5% [95% CI 77 
47.9‒68.6], respectively. Low PlGF outperformed gestational age, abdominal circumference and 78 
umbilical artery resistance index in predicting placental FGR. Very low PlGF (<12 pg/mL) was associated 79 
with shorter sampling-to-delivery intervals than normal PlGF (13 vs. 29.5 days, P<0.0001). 80 
Discussion: Low PlGF identifies small fetuses with significant underlying placental pathology and is a 81 
promising tool for antenatal discrimination of FGR from fetuses who are constitutionally-small. 82 
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Introduction  85 
Placentally-mediated fetal growth restriction (FGR) is a pathological process that reduces the 86 
growth trajectory of a fetus and increases the risk of stillbirth, preterm delivery, serious neonatal 87 
complications and lifelong sequelae [1-3]. FGR is clinically suspected when the ultrasound estimated 88 
fetal weight or fetal abdominal circumference is below the 10
th
 percentile for gestational age, or serial 89 
ultrasounds suggest decreasing growth velocity [4-6]. However, many fetuses with suspected FGR are 90 
small due to constitutional factors and are at low risk for adverse outcomes (“small but healthy” fetuses) 91 
[4].  92 
Antenatal discrimination of fetuses that are small due to placental dysfunction, rather than 93 
constitutionally-small, would improve clinical management by focusing care on fetuses that are truly at-94 
risk of adverse perinatal outcome, reducing surveillance fatigue and unnecessary intervention for 95 
pregnancies with constitutionally-small fetuses [7,8]. Placental biomarkers such as placental growth 96 
factor (PlGF), present in the maternal circulation, may provide an additional clinical tool for identifying 97 
placental FGR antenatally. Pilot work by our group suggests that low circulating levels of PlGF may 98 
characterize pregnancies complicated by FGR associated with significant placental pathology
 
[9] but 99 
larger studies are required to elucidate its clinical utility. In this study, we assessed the ability of PlGF to 100 
antenatally identify placental FGR, histologically confirmed after birth by the presence of significant 101 
placental pathology. Additionally, we assessed the sampling-to-delivery to determine if low PlGF is an 102 
indication of clinically-important FGR, with earlier delivery reflecting the physician’s decision to deliver 103 
in response to perceived perinatal risks.   104 
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Materials and Methods 105 
Study design 106 
Through the Global Pregnancy Collaboration (http://pre-empt.cfri.ca/colaboratory), we 107 
complemented a prospectively-recruited cohort of antenatally-suspected FGR pregnancies in Canada 108 
with two extant cohorts from New Zealand and the United Kingdom. All women provided written 109 
informed consent to participate in the study. 110 
Eligibility criteria was: antenatally-suspected FGR, defined as a fetal abdominal circumference(AC) 111 
<10
th
 percentile for gestational age (GA) on ultrasound by local criteria, maternal age 18‒45 years with a 112 
singleton pregnancy between 20
+0
‒41
+6
 weeks of gestation. Women with chronic or gestational 113 
hypertension and/or preeclampsia [10]
 
at enrolment, premature rupture of membranes at enrolment or 114 
a fetus with known chromosomal and/or congenital abnormalities at enrolment or confirmed after 115 
delivery were excluded. Blood samples were collected within 14 days of the ultrasound identification of 116 
FGR. The study was powered to estimate sensitivity and specificity within ±5% percentage points for the 117 
placental pathology-based analysis. Based on our pilot data [9], obtaining 95% sensitivity and 90% 118 
specificity (the lower 95% confidence interval limit of the point estimate in the pilot study) for PlGF to 119 
identify placental FGR required enrollment of 211 pregnancies with suspected FGR, assuming a 120 
conservative 35% rate of placental FGR. 121 
In Canada, women were recruited from inpatient and outpatient services at BC Women’s Hospital 122 
(Vancouver, H12-00504 C&W Research Ethics Board) and the Ottawa Hospital (Ottawa, 20120660 TOH 123 
Ethics Board) between April 2012‒June 2014, extending the published pilot study [9]. Baseline and post-124 
enrolment data about the women, their pregnancies and perinatal outcomes were abstracted from 125 
medical charts after delivery. Umbilical artery resistance index (RI) percentile was determined for GA at 126 
Doppler examination [11]. Birthweight percentile was determined using a Canadian national birthweight 127 
reference [12]. 128 
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A cohort of FGR pregnancies from Auckland, New Zealand with banked maternal blood samples and 129 
wax-embedded placental tissue (NTX/11/056/02 Northern Regional Ethics Committee) was identified 130 
through the Global Pregnancy Collaboration. Eligible women, both inpatients and outpatients, were 131 
recruited from National Women’s Hospital for a series of antenatal studies between 1993 and 1997 [13-132 
15]. Detailed data pertaining to these women, their pregnancies and perinatal outcomes were collected 133 
by research midwives after delivery and stored in a study database. From this database, women meeting 134 
our eligibility criteria were selected for inclusion. Umbilical artery RI percentile for GA was determined 135 
[11]. Birthweight percentile was determined using a New Zealand reference [17].
 
136 
A cohort of FGR pregnancies from the United Kingdom with banked maternal blood samples was 137 
identified through the Global Pregnancy Collaboration. The PELICAN-FGR Study (East London Research 138 
Ethics Committee, ref.10/H0701/117) [18]
 
recruited women presenting with reduced symphysis-fundal 139 
height between 2011‒2013. Fetal biometry was assessed by ultrasound and a maternal blood sample 140 
was collected during this antenatal visit.  Detailed data pertaining to these women, their pregnancies 141 
and perinatal outcomes were collected by research midwives after delivery and stored in a study 142 
database. From this database, women meeting our eligibility criteria were selected for inclusion. 143 
Birthweight percentile was determined using the Canadian standard as a recent multiethnic standard 144 
[12].  145 
PlGF analysis 146 
In all cohorts, maternal venous blood was collected by venepuncture using 10 mL EDTA plasma 147 
tubes. Plasma was isolated by centrifugation at 3000 rpm for 10 mins and stored at -80°C at all centres. 148 
Samples were batch assayed for PlGF using an automated immunoassay (Triage®, Alere, San Diego, CA, 149 
USA) [9,19,20]. The detection range of the assay is 12‒3000 pg/mL. Low PlGF was defined as a 150 
concentration <5th percentile for GA [20]. Very low PlGF was defined as a concentration <12pg/mL. 151 
Laboratory staff were masked to clinical and pathology data and clinicians were masked to PlGF results. 152 
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The integrity of the New Zealand samples after prolonged storage at -80°C was confirmed in a subset of 153 
cases prior to this analysis (Supplemental Figure S1). 154 
Placental pathology evaluation  155 
Placentas were collected at delivery (Canada and New Zealand). Trimmed placental weight was 156 
recorded and 4‒5 biopsies of villous parenchyma (1cm
3
 each) were randomly excised from the central 157 
and marginal regions of the placental disc. Tissue were fixed in 4% neutral buffered formalin (Canada) or 158 
10% neutral buffered formalin (New Zealand), paraffin-embedded, sectioned (5 µm) and stained with 159 
hematoxylin and eosin using standard protocol [21]. High-resolution digital images were taken (Aperio® 160 
ScanScope [Canada], Metasystems® VSlide [Auckland]). Images were stored on external hard drives for 161 
evaluation in Ottawa (Canada). 162 
A single, experienced placental pathologist (D.G.), masked to PlGF and clinical outcomes, examined 163 
the digital images of placental tissue using a Placental Examination Rubric (Supplemental Table S1) that 164 
evaluated and graded pathological lesions of maternal malperfusion, fetal villous stromal 165 
maldevelopment, villitis, perivillous fibrin deposition, fetal thrombotic vasculopathy, abruption, 166 
intraplacental hematoma and chorioamnionitis according to pre-specified definitions based on 167 
published guidelines [22-24].
 
A placental pathology grade (0 to 3) was assigned to each placenta as 168 
defined a priori in the Examination Rubric. A severity grade of 2 or 3 was considered to reflect placental 169 
FGR and a grade of 0 or 1 to reflect a constitutionally-small fetus. 170 
For 53 of the 109 Auckland women, tissue blocks were unavailable. For these cases, the placental 171 
pathology severity grade was assigned with the Examination Rubric (by D.G.) using placental pathology 172 
variables from the study database. These pathology variables were collected prospectively by direct 173 
microscopy by a single Perinatal Pathologist (by Y.C.) using pre-specified criteria during the original study 174 
period and included placental infarction, ischaemic changes, calcification, syncytial knots, villous 175 
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maturity, fibrin deposition, villitis, intraplacental hematoma and placental abruption ranked mild, 176 
moderate or severe.  177 
Statistics 178 
Analyses were performed using Prism 5.0 (GraphPad, CA, USA). P-values <0.05 were considered to 179 
indicate statistical significance. Normally-distributed data were reported using means with standard 180 
deviations and non-normally distributed data using medians with interquartile ranges. Categorical 181 
variables were reported using counts and proportions.  182 
For the placental pathology-based analysis, the ability of low PlGF (concentration <5
th
 percentile for 183 
GA) to predict placental FGR was assessed by calculating sensitivity, specificity, positive and negative 184 
predictive values, and positive and negative likelihood ratios with 95% confidence intervals.  These 185 
analyses were repeated to include only women with blood samples collected prior to 35 weeks of 186 
gestation to account for the physiological decline of PlGF towards term.
20 
Additionally, performance was 187 
assessed according to gestational age at onset (early vs late defined as <32 weeks and ≥32 weeks, 188 
respectively). Area under the receiver-operator characteristic (AUROC) curves were calculated for 189 
prediction of placental FGR by PlGF (as a percentile for GA at sampling) and for comparison, GA at the 190 
time of suspected FGR, ultrasound AC percentile, and umbilical artery RI percentile.  191 
In all cases (with and without placental histology), the sampling-to-delivery intervals between 192 
women with very low PlGF (<12 pg/mL), low PlGF (<5
th
 percentile, ≥12 pg/ml) and normal PlGF 193 
concentrations were compared. The percentage of ongoing pregnancies for each gestational age day 194 
after sampling was plotted using Kaplan-Meier survival curves and the median interval (in days) from 195 
sampling-to-delivery was compared between the groups using the log-rank test. 196 
  197 
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Results 198 
Placental pathology-based analysis (N=213)  199 
In total, 213 pregnancies with suspected FGR and placental tissue collected at delivery for placental 200 
pathology were included in the study (Canada: n=104, New Zealand: n=109; Figure 1). Of these 213 201 
women, 94 (44.1%) had low PlGF at enrolment. Women with low PlGF were enrolled at earlier GAs, had 202 
fetuses with smaller AC percentiles, delivered earlier and preterm, had babies with lower birthweight 203 
and birthweight percentile and were more likely to develop pregnancy hypertension after enrolment 204 
compared with women with normal PlGF (Table 1). All stillbirths occurred among women with low PlGF. 205 
The median interval between ultrasound identification of fetal AC <10
th
 percentile and blood sample 206 
collection was 1 day [interquartile range (IQR) [0‒5] for women with low PlGF and 0 days [0‒3] for 207 
women with normal PlGF (P=0.003).  208 
PlGF concentration by GA and placental pathology grade is shown in Figure 2. Of the 94 women with 209 
low PlGF at enrolment, 55 (58.5%) met the criteria of placental FGR whereas only 1 (0.8%) woman with 210 
normal PlGF had placental FGR (P<0.0001). All six stillbirths showed moderate or severe placental 211 
pathology (Grade 2, n=2; Grade 3, n=4).  212 
Low PlGF had 98.2% [95% confidence interval  90.5–99.9] sensitivity and 75.1% [67.6–81.7] 213 
specificity in identifying pregnancies with placental FGR as determined by placenta pathology grade. 214 
Negative and positive predictive values were 99.2% [95.4–99.9] and 58.5% [47.9–68.6], respectively 215 
(Table 2). Sensitivity analyses excluding women enrolled ≥35 weeks of pregnancy, or excluding the 53 216 
New Zealand women who had pathology graded based on the New Zealand study database, did not 217 
alter the results (Table 2).   218 
Low PlGF had an AUROC of 0.96 [0.93–0.98] to predict placental FGR. PlGF outperformed other 219 
readily-available clinical parameters (GA, AC percentile, umbilical artery RI percentile) in predicting 220 
placental FGR (Figure 3).  221 
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Sampling-to-delivery interval (N=411) 222 
In total, 411 women with suspected FGR (with and without placental pathology; Table 1) were 223 
included in this analysis (Canada: n=115, New Zealand: n=187, United Kingdom: n=109; Figure 1). Of 224 
these, 157 (38.2%) women had low PlGF at enrolment. Women with low PlGF were enrolled 225 
approximately one week earlier than women with normal PlGF and had fetuses with smaller ACs, higher 226 
umbilical artery RI percentiles, delivered earlier, had babies with lower birthweight and birthweight 227 
percentiles and were more likely to develop pregnancy hypertension after enrolment (Table 1). The 228 
median interval between ultrasound identification of fetal AC <10
th
 percentile and blood sampling for 229 
PlGF did not differ among women with low PlGF compared with those with normal PlGF (0 [0–2] versus 230 
0 [0–0], P=0.59).  231 
Very low PlGF was associated with a shorter sampling-to-delivery interval compared with normal 232 
PlGF (13.0 days versus 29.5 days, P<0.0001). Sample-to-delivery intervals were significantly shorter for 233 
women with very low and low PlGF when sampling occurred before 35 weeks of gestation: 14.0 days 234 
versus 33.5 versus 41.0 days, P<0.0001) (Figure 4). 235 
In total, there were 7 stillbirths and one neonatal death; 6 stillbirths and the neonatal death 236 
occurred in women with low PlGF and one stillbirth with normal PlGF. Low PlGF had 87.5% [47.4‒99.7] 237 
sensitivity and a specificity of 62.8% [57.9‒67.5] to predict pregnancies that end in stillbirth with 238 
negative and positive predictive values of 99.6% [97.8‒100.0] and 4.7% [1.8‒9.0], respectively. The 239 
positive likelihood ratio is 2.35 [1.8‒3.1] and the negative likelihood ratio is 0.2 [0.03‒1.2]. Thus, in this 240 
cohort, the post-test odds of perinatal death after a low PlGF result were 4.7% and the post-test odds 241 
after a normal PlGF were 0.4%.  242 
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Discussion 243 
Low maternal plasma PlGF (<5
th
 percentile for GA) identified fetuses with placental FGR with 244 
high sensitivity (98.2%), reasonable specificity (75.1%), high negative predictive value (99.2%) and 245 
modest positive predictive value (58.5%). The high sensitivity, high negative predictive value and low 246 
negative likelihood ratio (0.02) imply that a normal PlGF concentration (≥5
th
 percentile for GA) may be a 247 
useful ‘rule-out’ test for placental FGR, particularly among women presenting before 35 weeks’ 248 
gestation. Also, the AUC of 0.96 indicates that low PlGF appears to be more useful than available clinical 249 
parameters, such as GA, AC or umbilical artery RI for identifying placental FGR antenatally. Moreover, 250 
low PlGF identified women destined to deliver within a shorter period of time, so the reassurance of a 251 
normal PlGF may support expectant management to improve neonatal outcomes.  252 
Findings presented here support the growing body of evidence that PlGF is a marker for placentally-253 
mediated pregnancy complications [9,19,25-29]. PlGF is decreased in the circulation of women with 254 
preeclampsia, with the most significant decreases occurring in cases of early-onset disease (<34 weeks 255 
gestation) and those requiring delivery within 14 days of their clinical diagnosis [19,25-29]. Studies 256 
evaluating PlGF and normotensive FGR pregnancies are more limited with previous reports largely using 257 
infant birthweight percentile to define FGR [30-33]. These studies have reported decreased PlGF in 258 
women who delivered small-for-gestational age (SGA) neonates but poor diagnostic and/or predictive 259 
performance, probably related to study populations that included truly growth-restricted as well as 260 
constitutionally-small fetuses [4]. Defining placental FGR based on placental pathology (confirming the 261 
presence of lesions of placental dysfunction) as opposed to size alone allows for these populations of 262 
fetuses to be distinguished. Recently, decreased maternal PlGF was associated with late-onset SGA 263 
fetuses with histological lesions of placental underperfusion [34], suggesting an association between 264 
PlGF and placental dysfunction in these pregnancies as indicated by the presence of significant placental 265 
pathology. Our results support these findings as low PlGF characterised pregnancies with an outcome of 266 
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placental FGR in our study. Additionally, low PlGF may indicate the severity of fetal compromise in 267 
placental disease. Our sampling-to-delivery interval findings support previous studies that suggest that 268 
low PlGF may be associated with need for early delivery due to fetal decompensation in preeclampsia 269 
and FGR [18,29,35]. Finally, our findings also suggest that PlGF significantly alters the likelihood of 270 
subsequent perinatal death, which is consistent with the observation that stillbirths associated with FGR 271 
exhibit a greater degree of placental abnormality than live births with FGR [36]. Taken together, these 272 
data suggest that PlGF may be a useful test to identify fetuses at increased risk of stillbirth following 273 
identification that they are small.   274 
Major strengths of this study include the definition of pathologically-small babies according to 275 
placental pathological examination by a single perinatal pathologist, masked to PlGF results and clinical 276 
outcomes, as well as the use of graded placental pathology to identify the most significant cases. 277 
Accurate identification of placental FGR among fetuses suspected to be small is fundamental to 278 
identifying novel tools for antenatal identification of fetuses at-risk. To reduce observer subjectivity, a 279 
well-documented phenomenon associated with placental pathology [37], we developed a Placental 280 
Examination Rubric with pre-specified severity criteria for lesions of interest. Incorporating lesion 281 
severity into outcome definitions allows better definition of growth restriction of placental origin and 282 
the opportunity to better understand the association between placental pathology and biomarkers such 283 
as PlGF.  284 
Limitations of our study include the temporal differences between the Canadian and New Zealand 285 
cohorts included in the placental pathology-based analysis. The use of slightly different criteria to define 286 
placental pathology grades in 53 pregnancies from New Zealand may have resulted in some 287 
misclassification. However, we believe that all significant lesions would have been noted by the 288 
reporting pathologist, as our sensitivity analysis excluding the New Zealand cases without tissue 289 
available for histological examination by the Canadian pathologist, did not alter our findings. 290 
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Additionally, our study included cases of suspected FGR presenting over a wide range of gestational ages 291 
with a larger proportion of cases in the low PlGF group enrolled at earlier gestational ages. The inclusion 292 
of more early-onset cases in the low PlGF group may have influenced our findings as it is more often 293 
associated with placental dysfunction. However, our sub-analysis including only late-onset FGR cases 294 
shows that PlGF performs well as a rule-out test for placental dysfunction (high sensitivity and NPV).  295 
Future studies should determine how best to incorporate PlGF testing into clinical practice in the 296 
identification of these high-risk pregnancies and explore the relationship with existing antenatal 297 
surveillance tools. With an AUROC of 0.96, PlGF outperforms other biochemical markers of placental 298 
dysfunction such as human placental lactogen and progesterone in detecting FGR [38]. Inclusion of PlGF 299 
in a predictive model for fetal compromise after maternal perception of reduced fetal movements 300 
improved the AUROC from 0.75 (ultrasound only) to 0.88 (ultrasound+PlGF) [39]. Combining PlGF with 301 
umbilical artery Doppler did not improve the prediction of placental FGR in our study (data not shown), 302 
suggesting that PlGF may be a more powerful marker for placental FGR. Future studies should 303 
investigate the value of PlGF testing with other Doppler parameters such as uterine artery, middle 304 
cerebral artery and cerebral placental ratio indices for the prediction of adverse outcomes in FGR 305 
pregnancies [40].  We speculate that PlGF might be best as a rule-out test for placental dysfunction, 306 
offering reassurance that a fetus may be constitutionally-small and enable identification  of cases with 307 
at-risk fetuses who warrant closer clinical surveillance (i.e. more detailed Doppler studies). Our data 308 
advance knowledge in this field by suggesting that  PlGF  is able to discriminate fetuses with placental 309 
disease from those who are constitutionally-small would improve clinical management of the truly at-310 
risk fetus and reduce unnecessary intervention for women with pregnancies with constitutionally-small, 311 
healthy fetuses. In our view PlGF may be a promising tool for antenatal discrimination of growth 312 
restricted fetuses secondary to placental disease from those who are constitutionally-small. 313 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
Acknowledgments 314 
This study was supported by a grant (MOC 119545) from the Canadian Institutes of Health Research and 315 
salary awards from the Child and Family Research Institute (SJB; PvD; LAM), British Columbia Women’s 316 
Hospital and Health Centre (LAM), the Canadian Institutes of Health Research (JAH), and the Michael 317 
Smith Foundation for Health Research (JAH). In Auckland, funding was provided by Auckland Healthcare, 318 
the Health Research Council of New Zealand, the Lottery Health Grants Board and the Maurice and 319 
Phyllis Paykel Trust. Unrestricted grants-in-aid were received from Alere International to support the 320 
PELICAN FGR Study and for provision of Triage PlGF cartridges to the Canadian and New Zealand 321 
investigators. The Global Pregnancy Collaboration is supported by the Bill & Melinda Gates Foundation 322 
(Grant No: OPP1017337). 323 
 324 
We thank the BC Women’s and Children’s Department of Pathology and Laboratory Medicine, the 325 
Department of Anatomical Pathology at the Children’s Hospital of Eastern Ontario Department of 326 
Anatomical Pathology and the Department of Anatomy with Radiology at the University of Auckland for 327 
their support with this project. We also thank Rennae Taylor and Anna Hutfield for their assistance with 328 
the study. 329 
 330 
This manuscript is dedicated to the memory of our dear friend and colleague, Dr. Andrée Gruslin. 331 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
References 332 
1. Breeze ACG, Lees CC. Prediction and perinatal outcomes of fetal growth restriction. Semin Fet 333 
Neonat Med. 2007;12(5):383-97. 334 
2. Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and mortality among 335 
premature neonates. Am J Obstet Gynecol. 2004;191(2):481-7. 336 
3. Halliday HL. Neonatal management and long-term sequelae. Best Prac Res Cl Ob. 2009;23(6):871-80. 337 
4. Royal College of Obstetricians and Gynaecologists UK. Green-top Guideline No. 31: The investigation 338 
and management of the small-for gestational-age fetus. 2013. www.rcog.org.uk/clinical-guidance. 339 
5. Figueras F, Gratacos E. Update on the diagnosis and classification of fetal growth restriction and 340 
proposal of a stage-based management protocol. Fetal Diagn Ther. 2014;36(2):86-98. 341 
6. American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin Number 134: Fetal 342 
Growth Restriction. Obstet Gynecol. 2013; 121:1122-33. 343 
7. Zhang J, Merialdi M, Platt LD, Kramer MS. Defining normal and abnormal fetal growth: promises and 344 
challenges. Am J Obstet Gynecol. 2010;202(6):522-8. 345 
8. Soothill PW, Bobrow CS, Holmes R. Small for gestational age is not diagnosis. Ultrasound Obstet 346 
Gynecol. 1999;13:225-8. 347 
9. Benton SJ, Hu Y, Fang X, et al. Can placental growth factor identify placental intrauterine growth 348 
restriction in small for gestational age fetuses? Am J Obstet Gynecol. 2012;206(2):163.e1-7.  349 
10. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. SOGC clinical practice guideline: Diagnosis, 350 
evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 351 
2014;36(5):416-38. 352 
11. Acharya G, Wilsgaard T, Berntsen GKR, Maltau JM, Kiserud T. Reference ranges for serial 353 
measurements of umbilical artery Doppler indices in the second half of pregnancy. Am J Obstet 354 
Gynecol.2005;192:937-44. 355 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
12. Kramer M, Platt R, Wen S, et al. A new and improved population-based Canadian reference for birth 356 
weight for gestational age. Pediatrics. 2001:108(2):e35-42.  357 
13. McCowan LME, Harding JE, Roberts AB, et al.  A pilot randomized controlled trial of two regimens of 358 
fetal surveillance for small-for-gestational-age fetuses with normal results of umbilical artery 359 
Doppler velocimetry. Am J Obstet Gynecol. 2000:182(1):81-6.  360 
14. McCowan L, Harding J, Roberts A, et al. Administration of low dose aspirin to mothers with small for 361 
gestational age fetuses and abnormal umbilical Doppler studies to increase birthweight: a 362 
randomised double-blind controlled trial. BJOG. 1999;106:647-51. 363 
15. McCowan LME, Harding J, Stewart AW. Customised birthweight centiles predict SGA pregnancies 364 
with perinatal morbidity. BJOG. 2005;112:1026-33. 365 
16. McCowan LME, Harding JE, Stewart AW. Umbilical artery Doppler studies in small for gestational age 366 
babies reflect disease severity. BJOG. 2000;107:916-25. 367 
17. Guaran RL, Wein P, Sheedy M, Walstab J, Beischer NA. Update of growth percentiles for infants born 368 
in an Australian population. Aust N Z J Obstet Gynaecol. 1994;34:39-50. 369 
18. Griffin M, Seed P, Webster L, et al. Diagnostic accuracy of placental growth factor and ultrasound 370 
parameters to predict the small-for-gestational-age infant in women presenting with reduced 371 
symphysis-fundal height measurement. Ultrasound Obstet Gynecol. 2015;46(2):182-90.  372 
19. Benton SJ, Hu Y, Fang X, et al. Placental growth factor as a diagnostic test for pre-eclampsia: A 373 
performance comparison of two immunoassays. Am J Obstet Gynecol. 2011;205(5):469.e1-8.   374 
20. Saffer C, Olson G, Boggess KA, et al. Determination of placental growth factor (PlGF) in healthy 375 
pregnant women without signs or symptoms of preeclampsia. Pregnancy Hypertens. 2013;3(2):124-376 
32. 377 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
21. Warrander LK, Batra G, Bernatavicius G, et al. Maternal perception of reduced fetal movements is 378 
associated with altered placental structure and function. PLoS One. 2012;7(4):e34851. doi: 379 
10.1371/journal.pone.0034851. 380 
22. Redline RW, Ariel I, Baergen RN, et al. Fetal vascular obstructive lesions: Nosology and 381 
reproducibility of placental reaction patterns. Pediatr Dev Pathol. 2004;7(5):443-52.  382 
23. Redline RW, Boyd R, Campbell V, et al.  Maternal vascular underperfusion: Nosology and 383 
reproducibility of placental reaction patterns. Pediatr Dev Pathol. 2004;7(3):237-49.  384 
24. Redline RW, Faye-Petersen O, Heller D, et al.  Amniotic infection syndrome: Nosology and 385 
reproducibility of placental reactions patterns. Pediatr Dev Pathol. 2003;6(5):435-48. 386 
25. Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth 387 
factor: Evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet 388 
Gynecol. 2003;188(1):177-82. 389 
26. Levine RJ, Lam C, Qian C, et al.  Soluble endoglin and other circulating antiangiogenic factors in 390 
preeclampsia. N Engl J Med. 2006;355(10):992-1005.  391 
27. Powers RW, Roberts JM, Plymire DA, et al.  Low placental growth factor across pregnancy identifies 392 
a subset of women with preterm preeclampsia. Hypertension. 2012;60(1):239-46.  393 
28. Robinson CJ, Johnson DD, Chang EY, Armstrong DM, Wang W. Evaluation of placental growth factor 394 
and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet 395 
Gynecol. 2006;195(1):255-9.  396 
29. Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women 397 
with suspected preeclampsia: A prospective multicenter study. Circulation, 2013;128(19), 2121-31. 398 
30. Wallner W, Sengenberger R, Strick R, et al. Angiogenic growth factors in maternal and fetal serum in 399 
pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond). 2007;112(1):51-7.  400 
31. Levine R, Lam C, Qian C, et at. Soluble endoglin and other circulating angiogenic factors in 401 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
normotensive pregnancy with fetal growth restriction. Am J Obstet Gynecol. 2005;193(6):229-35.  402 
32. Ong CYT, Liao AW, Cacho AM, Spencer K, Nicolaides KH. First-trimester maternal serum levels of 403 
placenta growth factor as predictor preeclampsia and fetal growth restriction. Am J Obstet Gynecol. 404 
2001;98(4):608-11.  405 
33. Romero R, Nien JK, Espinoza J, et al.  A longitudinal study of angiogenic (placental growth factor) and 406 
anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors 407 
in normal pregnancy and patients destined to develop preeclampsia and deliver a small for 408 
gestational age neonate. J Matern Fetal Neonatal Med. 2008;21(1):9-23. 409 
34. Triunfo S, Lobmaier S, Parra-Saavedra M, et al.  Angiogenic factors at diagnosis of late-onset small-410 
for-gestational age and histological placenta underperfusion. Placenta. 2014;35(6):398-403. 411 
35. Chaiworapongsa T, Romero R, Whitten AE, et al. The use of angiogenic biomarkers in maternal blood 412 
to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-413 
eclampsia. J Matern Fetal Neonatal Med. 2015; Aug 25:1-15. [Epub ahead of print]  414 
36. Ptacek I, Smith A, Garrod A, et al. Quantitative assessment of placental morphology may identify 415 
specific causes of stillbirth. BMC Clinical Pathology, 2016, In Press. 416 
37. Redline R. The clinical implications of placental diagnoses. Semin Perinatol. 2015;39(1):2-8. 417 
38. Dutton PJ, Warrander LK, Roberts SA, et al. Predictors of poor perinatal outcome following maternal 418 
perception of reduced fetal movements – a prospective cohort study. PLoS One. 2012;7(7):e39784. 419 
doi:10.1371/journal.pone.0039784 420 
39. Higgins LE, Johnstone ED, Myers J, Sibley CP, Heazell AEP. Placental assessment aids identification of 421 
pregnancies with reduced fetal movement who experience adverse outcome. BJOG. 2015; 422 
Supplement.  423 
 424 
 425 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
Figure Legends 426 
 427 
Figure 1. Women with suspected FGR from study cohorts in Canada, New Zealand and the United 428 
Kingdom. In all cases, women were normotensive at enrolment with no documented signs or symptoms 429 
of preeclampsia, ruptured membranes, fetal anomalies, or fetal chromosomal abnormalities. Placentas 430 
were collected at delivery when possible Women were enrolled at study centres in Vancouver and 431 
Ottawa (Canada) from 2012 to 2014. Women from Auckland (New Zealand) were identified from among 432 
those enrolled in a previous study conducted from 1993 to 1997. Women were identified from the 433 
United Kingdom PELICAN-FGR Study conducted between 2011 to 2013. Placenta tissue collection at the 434 
time of delivery was not part of the original PELICAN-FGR Study design. 435 
 436 
Figure 2.  Maternal PlGF concentrations at the time of enrolment and placental pathology grading in 437 
213 pregnancies with suspected GR. PlGF concentration shown for normotensive women with no 438 
pathology (Grade 0, n=56; black squares), mild pathology (Grade 1, n=101; gray circles), moderate 439 
pathology (Grade 2, n=43; blue triangles) and severe pathology (Grade 3, n=13; red squares). PlGF was 440 
below the 5
th
 percentile cut-off for gestational age at sampling in all cases of severe pathology. The black 441 
arrows represent the cases that ended in stillbirth. The black dashed black line represents the 5
th
 442 
percentile PlGF concentration for gestational age at sampling [20].  443 
  444 
Figure 3. Area under the receiver operating characteristic curves for the prediction of placental FGR by 445 
PlGF and other clinical parameters of fetal assessment in 213 pregnancies with antenatally suspected 446 
FGR and placental histology. PlGF (percentile for gestational age at the time of enrolment) had an area 447 
under the curve of 0.96 (0.93-0.98) for predicting placental FGR (red line), outperforming gestational age 448 
at enrolment [0.73 (0.65-0.81); blue line], umbilical artery resistance index percentile at enrolment 449 
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[(0.66 (0.60-0.76); green line] and abdominal circumference percentile at enrolment [0.64 (0.54-0.73); 450 
purple line].  451 
 452 
Figure 4. Percentage of ongoing pregnancies from sampling to delivery in all 411 pregnancies with 453 
antenatally suspected FGR from Vancouver and Ottawa (Canada), Auckland (New Zealand) and the 454 
United Kingdom. Kaplan-Meier survival curves were used to plot the number of ongoing pregnancies for 455 
each day from sampling to delivery for each group. (A) Women with very low PlGF (PlGF <12pg/mL, 456 
n=57; black line) had shorter intervals from sampling to delivery (median: 13.0 days) than women with 457 
normal PlGF concentrations (median: 29.5 days, P-value<0.0001; n=254; blue line). Women with PlGF 458 
concentration <5
th
 percentile but ≥12 pg/mL (n=100; red line) had a median of 29 days from sampling to 459 
delivery. (B) The interval from sampling to delivery when sampling occurred before 35 weeks gestation 460 
in women with PlGF <12 pg/mL (n=39), PlGF <5
th
 percentile, ≥12pg/mL (n=72) and normal PlGF (n=147), 461 
respectively (14.0 days versus 33.5 days versus 41.0 days, P-value<0.0001). 462 
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Table 1. Characteristics of pregnancies with antenatally suspected growth restriction by PlGF concentration at enrolment from Canada, New 463 
Zealand and the United Kingdom included in the placenta pathology-based analysis (n=213, placental histology at delivery) and the sample-464 
to-delivery interval analysis (n=411). 465 
 466 
Characteristic Placental pathology-based analyses 
Mean±SD, median [IQR] or n (%) 
Sample-to-delivery interval analysis 
Mean±SD, median [IQR] or n (%) 
At enrolment 
Low PlGF 
(n=94/213) 
Normal PlGF  
(n=119/213) 
Low PlGF 
 (n=157/411) 
Normal PlGF 
(n=254/411) 
Maternal age (years) 30.4±5.8 28.5±6.1* 29.5±6.0 28.3±5.9 
Nulliparity 53 (56.4) 64 (53.8) 98 (62.4) 131 (51.6)* 
Smoking during pregnancy 12 (12.8) 33 (27.7)* 33 (21.0) 34 (26.8) 
Pre-pregnancy weight (kg) 61.5±11.5 60.7±14.0 60.9±13.4 60.3±12.3 
Maternal BP (mmHg)     
Systolic 113.3±12.5 108.0±13.0* 116.9 ± 16.2 111.2±12.9
†
 
Diastolic 68.4±8.7 65.7±8.6* 73.6 ± 13.5 69.9±10.6† 
Gestational age (weeks) 33.0 [29.8–35.0] 34.3 [32.3–36.0]* 33.3 [30.2–35.4] 34.4 [32.4–36.0]
†
 
 After 32 weeks 54 (57.4) 93 (78.2)* 96 (61.1) 195 (76.8)
†
 
Fetal ultrasound measurements 
(percentile for gestational age) 
    
Abdominal circumference  3.0 [1.0−5.0] 4.0 [2.5‒4.0]* 2.2 [1.0–5.0] 3.0 [1.5–6.4]* 
Estimated fetal weight 8.0 [3.0−16.0] 11.0 [4.5−26.0]* 4.0 [1.0–7.0] 6.0 [3.0–9.0]* 
Umbilical artery RI
ǂ
 88.2 [68.0−95.0] 72.2 [45.0−92.3]* 86.9 [75.1−94.9] 67.8 [39.5−90.2]
†
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(n=65) (n=93) (n=46) (n=179) 
Ultrasound to blood sampling interval 
(days) 
1 [0−5] 0 [0−3]* 0 [0−5] 0 [0−3]* 
Pregnancy Outcomes   
HDP developed after enrollment 25 (26.6) 7 (5.9)
†
 39 (24.8) 16 (6.3)
†
 
Pre-eclampsia
§ 
8 (8.5) 0 (0)* 11 (7.0) 2 (0.8)* 
Gestational hypertension
ǁ
  17 (18.1) 7 (5.9)* 28 (17.8) 14 (5.5)
†
 
Last ultrasound assessment prior to 
delivery (percentile for gestational age) 
    
Abdominal circumference  3.0 [1.0−4.0] 6.5 [2.3−11.0]* -- -- 
Estimated fetal weight 3.5 [2.0−8.3] 7.0 [3.0−19.0]* -- -- 
Umbilical artery RI
ǂ 
85.8 [54.2−96.3] 76.0 [45.3−90.3]* -- -- 
Gestational age at delivery (weeks) 36.1 [33.6−37.6] 38.3 [37.3−39.1]
†
 36.9 [34.5−38.1] 38.7 [37.7−40.0]
†
 
Pre-term delivery <37 weeks  58 (61.7) 22 (18.5)† 79 (50.3) 33 (13.0)† 
Birthweight (g) 1855±721 2529±402† 1993±724 2629±411† 
Birthweight percentile
¶ 
 2.0 [1.0−4.6] 5.0 [1.9−10.0]* 2.0 [1.0−6.1] 5.0 [2.0−11.4]† 
Birthweight <3
rd
 percentile 55 (58.5) 35 (29.4)
†
 87 (55.4) 72 (28.3)
†
 
Trimmed placental weight (g) 293±112 365±78
†
 -- -- 
Induction of labour for fetal indication 35 (37.2) 57 (47.9) 54 (34.4) 99 (40.0) 
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Caesarean delivery for fetal indication° 28 (29.8) 10 (8.4)† 41 (26.1) 19 (7.5)† 
Stillbirth 6 (6.4) 0 (0)* 6 (3.8) 1 (0.4)* 
Neonatal death  0 (0) 0 (0) 1 (0.6) 0 (0) 
Neonatal outcome     
APGAR <7 at 5minutes  12 (12.8) 1 (0.8)
†
 14 (8.9) 2 (0.8)
†
 
NICU admission >48 hours 26 (27.7) 12 (10.1)* 31 (19.7) 15 (5.9)
†
 
Placental IUGR     
Pathology grade 2 or 3 55 (58.5) 1 (0.8)
†
 -- -- 
FGR: fetal growth restriction; HDP: hypertensive disorders of pregnancy; IQR: interquartile range; NICU: neonatal intensive care unit; PlGF: 467 
placental growth factor; RI: resistance index.   468 
Comparisons were performed between columns with women with low PlGF at the time of enrolment as the comparator group to women with 469 
normal PlGF concentration at enrolment for each study analysis. 470 
*P<0.05 ; 
†
P<0.001 471 
ǂ
Umbilical artery resistance index percentile was determined for gestational age week at the time of Doppler examination [11]. 472 
§ 
Preeclampsia was defined as hypertension (blood pressure ≥140/90 mm Hg, on at least two occasions >4 hours apart after 20 weeks gestation) 473 
and new onset proteinuria (≥2+ dipstick reading, ≥0.3 g/day by 24 hour urine collection, or ≥30 mg/mmol by protein:creatinine ratio)[10].  474 
ǁ 
Gestational hypertension was defined as non-proteinuric hypertension developing at ≥20
+0
 weeks gestation [10].
 
475 
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¶ 
Birthweight percentiles were determined based on Canadian [12] (population-based) and New Zealand [17] (customized) birthweight 476 
references.  477 
° Defined as absent or reversed end diastolic flow and/or an abnormal/non-reassuring heart rate trace during intrapartum monitoring.   478 
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Table 2. Sensitivity and specificity of a low PlGF (concentration <5
th
 percentile for gestational age) to identify placental FGR in 213 479 
pregnancies with antenatally suspected FGR. 480 
 481 
+LR: positive likelihood ratio; -LR: negative likelihood ratio; CI: 95% confidence interval; NPV: negative predictive value; PPV: positive predictive 482 
value.  483 
* Due to lack of false positive cases, a value of 0.5 was input into the 2x2 contingency table in order to calculate the negative likelihood ratio.  484 
 
Sensitivity 
[95% CI] 
Specificity 
[95% CI] 
PPV 
[95% CI] 
NPV 
[95% CI] 
+LR 
[95% CI] 
-LR 
[95% CI] 
Enrolment at 
any gestational 
age 
(n=213) 
98.2 [90.5‒99.9] 75.1 [67.6‒81.7] 58.5 [47.9‒68.6] 99.2 [95.4‒99.9] 3.95 [3.01‒5.20] 0.024 [0.0030‒0.17] 
Enrolment  <35 
weeks gestation 
(n=141) 
100.0 [92.3‒100.0] 74.7 [64.8‒83.1] 65.7 [53.4‒76.7] 100.0 [95.0‒100.0] 3.92 [2.77‒5.54] 0.014 [0.0010‒0.23]* 
Enrolment <32 
weeks gestation 
(n=66) 
100.0 [89.1‒100.0]  76.5 [58.9‒89.3] 80.0 [64.4‒91.0] 100.0 [86.8‒100.0] 4.25 [2.31‒7.77] 0.004 [00.10‒0.32]* 
Enrolment ≥32 
weeks gestation 
(n=147) 
95.8 [78.9‒98.9] 74.8 [66.2‒82.2] 42.6 [29.2‒56.8] 98.9 [94.2‒100.0] 3.80 [2.77‒5.21] 0.056 [0.0080‒0.38] 
New Zealand 
database cases 
excluded 
(n=160) 
98.0 [89.2‒100.0] 71.2 [61.8‒79.4] 60.0 [48.4‒70.8] 98.8 [93.2‒100.0] 3.40 [2.53‒4.56] 0.029 [0.004‒0.20] 
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Sample-to-delivery interval analysis (n=411)  
5 women withdrew after consent 
14 women delivered at other 
institutions/out of province 
n = 115 
Canada 
n = 134 
New Zealand 
n = 249 
Suspected fetal growth restriction 
(fetal abdominal circumference <10
th
 
percentile) 
Normotensive women, 18-45 years of age 
Singleton pregnancy, ≥20 weeks gestation;  
no fetal anomalies or fetal chromosomal 
abnormalities 
Placental pathology-based analysis (n=213) 
  
No placenta collected 
n = 11 
Placenta collected  
n = 104 
Placenta collected  
n = 109 
No placenta collected 
n = 78 
10 plasma samples with 
insufficient volume for 
testing 
52 women were 
hypertensive at enrolment 
n = 187 
Canada 
n = 115 
New Zealand 
n = 187 
United Kingdom* 
n = 109 
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Figure 4 
A.  
Days from sampling to delivery
%
 
O
n
g
o
i
n
g
 
P
r
e
g
n
a
n
c
i
e
s
0 7 14 21 28 35 42 49 56 63 70 77 84 91 98 105 112 119 126 133 140
0
20
40
60
80
100
Normal PlGF (n=254)
PlGF <5th percentile, ≥12 pg/mL (n=100)
PlGF <12 pg/mL (n=57)
B.  
Days from sampling to delivery
%
 
O
n
g
o
i
n
g
 
P
r
e
g
n
a
n
c
i
e
s
0 7 14 21 28 35 42 49 56 63 70 77 84 91 98 105 112 119 126 133 140
0
20
40
60
80
100
Normal PlGF (n=147)
PlGF <5th percentile, ≥12 pg/mL (n=72)
PlGF <12 pg/mL (n=39)
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Highlights 
 
• Low PlGF is associated with significant placental pathology in FGR pregnancies 
• Low PlGF has high sensitivity and moderate specificity in identifying placental FGR  
• Low PlGF is associated with shorter sampling-to-delivery intervals than normal PlGF 
• Low PlGF has a greater post-test probability of stillbirth than normal PlGF  
